Akero Therapeutics, Inc.
AKRO
Rangering i aksjer
#3738
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Aksjekurs
$54.65
Sist synkronisert: 2025-12-09
Markedsverdi
$4.50B
Endring (1 dag)
0.00%
Endring (1 år)
1.37%
Land
US
Handel Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Antall utestående aksjer for Akero Therapeutics, Inc. (AKRO)
Antall utestående aksjer per September 2025: 82.01M
Ifølge Akero Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 82.01M. Ved slutten av December 2023 hadde selskapet 52.57M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Akero Therapeutics, Inc. (AKRO) fra 2017 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 82.01M | 22.15% |
| 2024 | 67.14M | 27.71% |
| 2023 | 52.57M | 34.84% |
| 2022 | 38.98M | 11.94% |
| 2021 | 34.83M | 10.69% |
| 2020 | 31.46M | 108.77% |
| 2019 | 15.07M | -28.99% |
| 2018 | 21.22M | -25.67% |
| 2017 | 28.56M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 209.60% |
US
|
|
| 396.00M | 382.88% |
US
|
|
| 478.91M | 483.98% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -24.17% |
NL
|
